For immediate release:
Pleasanton, CA – March 14, 2018
CBT Pharmaceuticals (CBT), a U.S. and China-based innovative biopharmaceutical company committed to becoming a leader in the discovery and development of oncology combination therapies, today announced that the company will present at two upcoming investor conferences:
- March 23, 2018 – Future Leaders in the Biotech Industry at 2:45 – 3:00 p.m. EST in New York, N.Y.
- March 28, 2018 – China Healthcare Investment Conference (CHIC) at 3:15 – 5:15 p.m. CST in Shanghai, P.R. China
About CBT Pharmaceuticals, Inc.
CBT Pharmaceuticals, Inc. is an innovative biopharmaceutical company committed to becoming a global leader in the discovery and development of oncology combination therapies by focusing on therapeutics harnessing the immune system and targeting specific molecular pathways to tame cancer. The company’s existing pipeline of four development-stage assets includes two novel humanized monoclonal antibodies – CBT-501, targeting the Programmed Death-1 (PD-1) membrane receptor of immune cells, as well as Programmed Death Ligand-1 (PD-L1) (CBT-502) that restores the body’s immune system to recognize and kill cancer cells. In addition, CBT-101, is an oral c-MET inhibitor targeting the epithelial to mesenchymal transition (EMT) pathway and CBT-102, an oral multi-targeted kinase inhibitor that targets uncontrolled growth signaling pathways. The company was founded in 2016.
MacDougall Biomedical Communications